Although gout is a common disease that may have serious consequences, numerous studies show that gout is often misdiagnosed and that its management is suboptimal. New evidence-based guidelines for the management of gout from the European League Against Rheumatism (EULAR), published on July 25, 2016, have been developed in the hopes of remedying these issues.
London, United Kingdom—Inflammatory bowel disease (IBD) is often associated with psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), explained Stefan Schreiber, MD, Christian-Albrechts-University, Kiel, Germany. The risk for Crohn’s disease is approximately 4 times higher in patients with psoriasis, compared with the general population; it is even higher in patients with PsA and AS.
London, United Kingdom—An early-phase study of bimekizumab, a monoclonal antibody potently and selectively inhibiting interleukin (IL)-17A and IL-17F, demonstrated strong responses in skin and joints of patients with psoriatic arthritis. IL-17A and IL-17F, key proinflammatory cytokines, are overexpressed in psoriatic skin lesions, said Sophie Glatt, MD, UCB Celltech, Slough, United Kingdom, in an oral presentation at the 2016 European League Against Rheumatism Annual Congress.
London, United Kingdom—Evidence is mounting in support of using the investigational monoclonal antibody anifrolumab in patients with severe systemic lupus erythematosus (SLE). Results from the phase 2b MUSE trial—which were first presented at the 2015 American College of Rheumatology Annual Scientific Meeting, and then in greater detail at the recent 2016 European League Against Rheumatism Annual Congress—show that in patients with moderate-to-severe SLE, anifrolumab reduces disease activity across a wide range of clinical end points, and is safe and tolerable.
London, United Kingdom—Women with systemic lupus erythematosus (SLE) appear to have a higher risk for cervical cancer and premalignant cervical changes compared with women in the general population, according to the results of a large Swedish registry study presented at the 2016 annual meeting of the European League Against Rheumatism (EULAR). The highest risk was observed in women treated with immunosuppressive agents compared with those treated with antimalarial medications, the researchers also observed.
Chicago, IL—In a recent press release by the American Medical Association (AMA), the organization announced the launch of 8 new educational modules to enable practice improvement and promote innovation in the delivery of care.
San Francisco, CA—Reductions in postinitiation treatment costs partly offset, but did not eliminate, the added cost of repository corticotropin injection (RCI) therapy for patients with systemic lupus erythematosus (SLE), researchers behind the analysis of an administrative claims database have found.
Celecoxib is superior to acetaminophen in relieving pain in patients with chronic, nonspecific low back pain, Canadian investigators have found.
London, United Kingdom—Monitoring antidrug antibody formation in those receiving biologic disease-modifying antirheumatic drugs can inform treatment decisions in patients with rheumatic diseases. In particular, patients who developed antibodies to infliximab (Remicade) cross-reacted with the infliximab biosimilar CT-P13—marketed as Remsima or Inflectra—according to data from a multicenter, controlled study of patients with rheumatoid arthritis (RA) and spondylo­arthritis (SpA) presented at the 2016 European League Against Rheumatism Annual Congress.
  • Growing Burden of Arthritis in the United States
  • Patients with Lupus at Risk for End-Stage Renal Disease
Page 1 of 2
Results 1 - 10 of 17
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology